Yahoo · Sep 7, 2026
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
NV
NASDAQ · NVCR
NovoCure Limited
Healthcare · Medical - Instruments & Supplies
$17.94
Down-$1.09 (-6.08%)
Updated Sep 9, 2026, 12:34 AM
SID Score
7.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.53B
- P/E ratio
- -8.6
- Dividend yield
- 0.00%
- 52-week range
- $10.14 – $21.45
- Volume
- 732.17K
- Avg. volume
- 1.71M
Price performance
NVCR price history
1M range · 19 trading sessions · Daily adjusted prices
NVCR closed at $17.94 after 19 trading sessions, up 1.59% for the selected period.
- Last close
- $17.94
- Period change
- +1.59%
- Period low
- $16.76
- Period high
- $18.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $17.53 | $18.015 | $17.47 | $17.94 | 732.17K |
| Sep 3, 2026 | $17.94 | $18.045 | $17.42 | $17.64 | 613.41K |
| Sep 2, 2026 | $17.88 | $18.59 | $17.50 | $17.83 | 1.32M |
| Sep 1, 2026 | $17.36 | $17.875 | $17.29 | $17.38 | 800.36K |
| Aug 31, 2026 | $17.55 | $17.97 | $17.39 | $17.65 | 914.82K |
| Aug 28, 2026 | $17.99 | $18.159 | $17.42 | $17.82 | 855.58K |
| Aug 27, 2026 | $17.92 | $18.21 | $17.48 | $17.99 | 763.44K |
| Aug 26, 2026 | $17.43 | $17.97 | $17.15 | $17.89 | 1.27M |
| Aug 25, 2026 | $16.975 | $17.64 | $16.92 | $17.62 | 902.96K |
| Aug 24, 2026 | $17.02 | $17.055 | $16.33 | $16.76 | 1.61M |
| Aug 21, 2026 | $17.75 | $17.825 | $17.01 | $17.10 | 1.4M |
| Aug 20, 2026 | $18.12 | $18.61 | $17.48 | $17.77 | 955.71K |
| Aug 19, 2026 | $17.40 | $18.34 | $17.38 | $18.20 | 4.84M |
| Aug 18, 2026 | $17.25 | $17.73 | $17.08 | $17.24 | 792.64K |
| Aug 17, 2026 | $16.78 | $17.76 | $16.78 | $17.53 | 1.45M |
| Aug 14, 2026 | $17.23 | $17.23 | $16.80 | $16.95 | 681.34K |
| Aug 13, 2026 | $17.53 | $17.745 | $17.18 | $17.38 | 637.13K |
| Aug 12, 2026 | $17.66 | $17.675 | $17.22 | $17.59 | 764.68K |
| Aug 11, 2026 | $17.34 | $17.8255 | $17.29 | $17.66 | 923.86K |
Latest NVCR news
The latest Smart Investors Daily articles mentioning NVCR.
Stock researchCompany · Overview
NVCR research
Overview
Company profile and research snapshot.
Company profile
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.25
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 24, 2026 | Wedbush | Neutral | — |
| Jul 23, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 13, 2026 | JP Morgan | Neutral | — |
| Jun 18, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | Wells Fargo | Equal-Weight | — |
News briefing
Generated Sep 8, 2026, 9:18 PM
Why Is NVCR Down Today?
NovoCure Limited shares fell 6.08% today following disclosure of a cybersecurity incident involving patient data exposure. The breach represents a significant compliance and reputational risk for the medical device company, which relies heavily on patient trust and regulatory standing.
Bottom line: Today's 6.08% decline reflects investor concern over the disclosed cybersecurity incident and its regulatory, compliance, and reputational implications. While the near-term outlook faces headwinds, investors should monitor management's transparency regarding the incident scope, remediation efforts, and any regulatory actions—these factors will likely drive the stock's recovery trajectory in coming weeks.
Yahoo · Sep 2, 2026
Novocure Announces Upcoming Investor Events
BAAR, Switzerland, September 02, 2026--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.
Yahoo · Aug 28, 2026
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SeekingAlpha · Jul 24, 2026
NovoCure: Why I'm Fading The Q2 Earnings Rally
NovoCure stock remains a Hold: Q2 revenue rose 16% and EBITDA guidance improved, but cash generation lags. Click to read my analysis.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
